A Phase 2a, Double-Blind, Placebo-Controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

Ioannis Psallidas,Vibeke Backer,Piotr Kuna,Robert Palmér,Sofia Necander,Malin Aurell,Katarina Korsback,Ziad Taib,Mahdi Hashemi,Per Gustafson,Sara Asimus,Stephen Delaney,Katerina Pardali,Fanyi Jiang,Joachim Almquist,Sam Jackson,Robert L. Coffman,David Keeling,Tariq Sethi

A Phase 2a, Double-Blind, Placebo-Controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma.

2020

Ioannis Psallidas
Vibeke Backer
Piotr Kuna
Robert Palmér
Sofia Necander
Malin Aurell
Katarina Korsback
Ziad Taib
Mahdi Hashemi
Per Gustafson
Sara Asimus
Stephen Delaney
Katerina Pardali
Fanyi Jiang
Joachim Almquist
Sam Jackson
Robert L. Coffman
David Keeling
Tariq Sethi

Rationale: To examine the potential of TLR9 activation to modulate the Type-2 immune response in asthma. Objectives: To evaluate efficacy and safety of AZD1419, an inhaled TLR9 agonist, in a phase ...

Keywords:

th1 response
double blind
Medicine
Placebo
Internal medicine
Immune system
TLR9
Agonist
Randomized controlled trial
Asthma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations